UBS Group
CELZ icon

UBS Group’s Creative Medical Technology CELZ Stock Holding History

UBS Group’s Portfolio CELZ Stock Details CELZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.99K Buy
2,061
+2,060
+206,000% +$4.45K ﹤0.01% 9255
2026
Q1 		$2 Sell
1
-10
-91% -$20 ﹤0.01% 10373
2025
Q4 		$22 Buy
11
+9
+450% +$27 ﹤0.01% 10350
2025
Q3 		$7 Hold
2
– – ﹤0.01% 10212
2025
Q2 		$5 Hold
2
– – ﹤0.01% 10175
2025
Q1 		$4 Buy
2
+1
+100% +$3 ﹤0.01% 10146
2024
Q4 		$2 Sell
1
-2,724
-100% -$8.23K ﹤0.01% 9852
2024
Q3 		$8.45K Buy
+2,725
New +$9.23K ﹤0.01% 7839
2024
Q2 		– Sell
-3,064
Closed -$16K – 9572
2024
Q1 		$16K Buy
3,064
+2,022
+194% +$9.41K ﹤0.01% 7023
2023
Q4 		$4.8K Sell
1,042
-50
-5% -$228 ﹤0.01% 7824
2023
Q3 		$5.37K Buy
1,092
+1,072
+5,360% +$5.48K ﹤0.01% 7376
2023
Q2 		$93 Buy
+20
New +$116 ﹤0.01% 8521
2023
Q1 		– Sell
-3,090
Closed -$11.7K – 9656
2022
Q4 		$11.7K Buy
3,090
+2,012
+187% +$8.28K ﹤0.01% 8360
2022
Q3 		$5K Buy
+1,078
New +$7.31K ﹤0.01% 9172
2022
Q2 		– Sell
-916
Closed -$36K – 10368
2022
Q1 		$36K Buy
+916
New +$20.4K ﹤0.01% 6811

Other funds holding CELZ

Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
GRP
Global Retirement Partners San Rafael, California $6.54B AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group's CELZ Position: Q2 2026 in Review

UBS Group increased its Creative Medical Technology (CELZ) stake by 206,000% in Q2 2026, buying an estimated $4.45K and bringing the position to 2,061 shares worth $2.99K. The position accounts for ﹤0.01% of the portfolio, ranked #9255.

UBS Group first reported a position in CELZ in Q1 2022 and has held it in 15 quarters since. The position peaked at $36K in Q1 2022. 15 funds tracked by Wall St. Rank hold CELZ as of Q2 2026.

  • UBS Group held 2,061 shares of Creative Medical Technology worth $2.99K as of Q2 2026.
  • UBS Group bought 2,060 Creative Medical Technology shares in Q2 2026, an estimated $4.45K.
  • Creative Medical Technology made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #9255 holding.
  • UBS Group first reported a position in Creative Medical Technology in Q1 2022 and has held it in 15 quarters since.
  • UBS Group's Creative Medical Technology position peaked at $36K in Q1 2022.
  • 15 funds tracked by Wall St. Rank held Creative Medical Technology as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.